A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma (RTOG 1010)
University of Arizona Radiation Oncology Clinical Research is conducting a research study to evaluate the safety and efficacy of Trastuzumab. This study is being done to compare the effects, good and/or bad, of the addition of trastuzumab, a drug that targets HER2 (Human Epidermal Growth Factor 2 –found in certain types of cancer cells) to standard chemotherapy, radiation, and surgery for patients with HER2 positive esophageal cancer. Subjects will receive chemotherapy of paclitaxel and carboplatin, radiation therapy, and surgery for their esophageal cancer. Subjects will be randomized to receive or not to receive trastuzumab.
If you are interested in this study you should:
- Be at least 18 years of age
- Have a Diagnosis of Esophageal Cancer
- Have not started treatment for esophageal cancer yet
- Recently had a History and Physical
If you are interested in finding out more about this study, please call us at 520-626-6800. One of our staff will be happy to give you further information regarding this study and will schedule an appointment to allow you to discuss the study in more detail with one of our physicians. We appreciate your interest in this study and look forward to making your research experience a pleasant one. Feel free to pass this information along to anyone you think may be interested.
An Institutional Review Board responsible for human subjects research at The University of Arizona reviewed this research project and found it to be acceptable, according to applicable state and federal regulations and University policies designed to protect the rights and welfare of participants in research.